TSMDA: Target and symptom-based computational model for miRNA-disease-association prediction

Mitigating off-target effects of small RNAs: conventional approaches, network theory and artificial intelligence

Three types of highly promising small RNA therapeutics, namely, small interfering RNAs (siRNAs), microRNAs (miRNAs) and the RNA subtype of antisense oligonucleotides (ASOs), offer advantages over small-molecule drugs. These small RNAs can target any gene product, opening up new avenues of effective and safe therapeutic approaches for a wide range of diseases. In preclinical research, synthetic small RNAs play an essential role in the investigation of physiological and pathological pathways as silencers of specific genes, facilitating discovery and validation of drug targets in different conditions. Off-target effects of small RNAs, however, could make it difficult to interpret experimental results in the preclinical phase and may contribute to adverse events of small RNA therapeutics. Out of the two major types of off-target effects we focused on the hybridization-dependent, especially on the miRNA-like off-target effects. Our main aim was to discuss several approaches, including sequence design, chemical modifications and target prediction, to reduce hybridization-dependent off-target effects that should be considered even at the early development phase of small RNA therapy. Because there is no standard way of predicting hybridization-dependent off-target effects, this review provides an overview of all major state-of-the-art computational methods and proposes new approaches, such as the possible inclusion of network theory and artificial intelligence (AI) in the prediction workflows. Case studies and a concise survey of experimental methods for validating in silico predictions are also presented. These methods could contribute to interpret experimental results, to minimize off-target effects and hopefully to avoid off-target-related adverse events of small RNA therapeutics. LINKED ARTICLES: This article is part of a themed issue Non-coding RNA Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc.

Mitigating sub-synchronous oscillation using intelligent damping control of DFIG based on improved TD3 algorithm with knowledge fusion

The occurrence of sub-synchronous oscillation (SSO) phenomenon in doubly-fed induction generators (DFIGs)-based wind turbines threatens the secure and stable operation of the power grid. Conventional sub-synchronous damping controllers encounter challenges in adapting to the dynamic operating conditions of power systems. This paper introduces an Intelligent Sub-Synchronous Damping Controller (I-SSDC) for DFIGs that integrates deep reinforcement learning (DRL) and knowledge to address the limitations of conventional methods for SSO mitigation. The initial step involves formulating a framework for I-SSDC using the improved twin delayed deep deterministic policy gradient (TD3) algorithm incorporating Softmax. Following this, a surrogate model is constructed, employing Weighted Linear Regression and regularization. This model is designed to identify the predominant influencing factors of SSO, focusing on the selection of the output signal (installation position) to optimize decision-making in I-SSDC. The objective is to enhance the controller's environmental adaptability and interpretability. Moreover, knowledge and experience related to SSOs are integrated into agent training to improve the exploration efficiency of the agent. Case studies under various operating conditions of the test power system validate the efficacy of the proposed I-SSDC in suppressing SSOs.

DGAMDA: Predicting miRNA-disease association based on dynamic graph attention network

MiRNA (microRNA)-disease association prediction has essential applications for early disease screening. The process of traditional biological experimental validation is both time-consuming and expensive. However, as artificial intelligence technology continues to advance, computational methods have become efficient tools for predicting miRNA-disease associations. These methods often rely on the combination of multiple sources of association data and require improved feature mining. This study proposes a dynamic graph attention-based association prediction model, DGAMDA, which combines feature mapping and dynamic graph attention mechanisms through feature mining on a single miRNA-disease association network. DGAMDA effectively solves the problems of feature heterogeneity and inadequate feature mining by previous static graph attention mechanisms and achieves high-precision feature mining and association scoring prediction. We conducted a five-fold cross-validation experiment and obtained the mean values of Accuracy, Precision, Recall, and F1-score, which were .8986, .8869, .9115, and .8984, respectively. Our proposed model outperforms other advanced models in terms of experimental results, demonstrating its effectiveness in feature mining and association prediction based on a single association network. In addition, our model can also be used to predict miRNAs associated with unknown diseases.

Advances in applications of artificial intelligence algorithms for cancer-related miRNA research

MiRNAs are a class of small non-coding RNAs, which regulate gene expression post-transcriptionally by partial complementary base pairing. Aberrant miRNA expressions have been reported in tumor tissues and peripheral blood of cancer patients. In recent years, artificial intelligence algorithms such as machine learning and deep learning have been widely used in bioinformatic research. Compared to traditional bioinformatic tools, miRNA target prediction tools based on artificial intelligence algorithms have higher accuracy, and can successfully predict subcellular localization and redistribution of miRNAs to deepen our understanding. Additionally, the construction of clinical models based on artificial intelligence algorithms could significantly improve the mining efficiency of miRNA used as biomarkers. In this article, we summarize recent development of bioinformatic miRNA tools based on artificial intelligence algorithms, focusing on the potential of machine learning and deep learning in cancer-related miRNA research.

MicroRNAs: Small but Key Players in Viral Infections and Immune Responses to Viral Pathogens

Since the discovery of microRNAs (miRNAs) in C. elegans in 1993, the field of miRNA research has grown steeply. These single-stranded non-coding RNA molecules canonically work at the post-transcriptional phase to regulate protein expression. miRNAs are known to regulate viral infection and the ensuing host immune response. Evolving research suggests miRNAs are assets in the discovery and investigation of therapeutics and diagnostics. In this review, we succinctly summarize the latest findings in (i) mechanisms underpinning miRNA regulation of viral infection, (ii) miRNA regulation of host immune response to viral pathogens, (iii) miRNA-based diagnostics and therapeutics targeting viral pathogens and challenges, and (iv) miRNA patents and the market landscape. Our findings show the differential expression of miRNA may serve as a prognostic biomarker for viral infections in regard to predicting the severity or adverse health effects associated with viral diseases. While there is huge market potential for miRNA technology, the novel approach of using miRNA mimics to enhance antiviral activity or antagonists to inhibit pro-viral miRNAs has been an ongoing research endeavor. Significant hurdles remain in terms of miRNA delivery, stability, efficacy, safety/tolerability, and specificity. Addressing these challenges may pave a path for harnessing the full potential of miRNAs in modern medicine.

Prediction of biomarker-disease associations based on graph attention network and text representation

MOTIVATION

The associations between biomarkers and human diseases play a key role in understanding complex pathology and developing targeted therapies. Wet lab experiments for biomarker discovery are costly, laborious and time-consuming. Computational prediction methods can be used to greatly expedite the identification of candidate biomarkers.

RESULTS

Here, we present a novel computational model named GTGenie for predicting the biomarker-disease associations based on graph and text features. In GTGenie, a graph attention network is utilized to characterize diverse similarities of biomarkers and diseases from heterogeneous information resources. Meanwhile, a pretrained BERT-based model is applied to learn the text-based representation of biomarker-disease relation from biomedical literature. The captured graph and text features are then integrated in a bimodal fusion network to model the hybrid entity representation. Finally, inductive matrix completion is adopted to infer the missing entries for reconstructing relation matrix, with which the unknown biomarker-disease associations are predicted. Experimental results on HMDD, HMDAD and LncRNADisease data sets showed that GTGenie can obtain competitive prediction performance with other state-of-the-art methods.

AVAILABILITY

The source code of GTGenie and the test data are available at: https://github.com/Wolverinerine/GTGenie.

Impact of smoking-induced dysregulated human miRNAs in chronic disease development and their potential use in prognostic and therapeutic purposes

MicroRNAs (miRNAs) are evolutionary conserved small noncoding RNA molecules with a significant ability to regulate gene expression at the posttranscriptional level either through translation repression or messenger RNA degradation. miRNAs are differentially expressed in various pathophysiological conditions, affecting the course of the disease by modulating several critical target genes. As the persistence of irreversible molecular changes caused by cigarette smoking is central to the pathogenesis of various chronic diseases, several studies have shown its direct correlation with the dysregulation of different miRNAs, affecting numerous essential biological processes. This review provides an insight into the current status of smoking-induced miRNAs dysregulation in chronic diseases such as COPD, atherosclerosis, pulmonary hypertension, and different cancers and explores the diagnostic/prognostic potential of miRNA-based biomarkers and their efficacy as therapeutic targets.